COMPPARE Newsroom Prostate cancer research news
The latest information for patients.
prostate Cancer News from around the world
Comparing Medicare Drug Plans May Ease Prostate Cancer Financial Toxicity
Less than 30% of patients report comparing drug costs before selecting a Medicare Part D plan.
Early-Onset Cancer Morbidity Continuing to Increase
Main risk factors underlying early-onset cancers are dietary risk factors, alcohol consumption, and tobacco use
Prostate Cancer Outcomes Worse With Higher Periprostatic vs Serum Testosterone
Local testosterone delivery to the prostate bed might be a better marker of post-prostatectomy outcomes than serum testosterone in some men.
Prostate Cancer Biochemical Recurrence Risk Stratification Falls Short
More stringent criteria are needed to define truly low-risk biochemical recurrence of prostate cancer following surgery and radiation treatment.
Health News from The NIH
A potential blood test for Parkinson’s disease
A blood test that measures damage to cells’ mitochondria was able to distinguish people with Parkinson’s disease from those without.
Tiny implanted devices give insights for treating brain tumors
A tiny device implanted during brain surgery could help provide personalized information about a tumor’s potential responses to cancer-fighting drugs.
Cold virus may set the stage for Long COVID
Prior infection with a common cold coronavirus may predispose some people to develop Long COVID.
Chronic traumatic encephalopathy in young athletes
In a study of brains from contact sport players who died before reaching 30, more than 40% had chronic traumatic encephalopathy, or CTE.
News from COMPPARE
New Patient Surveys to Assist in Designing the…
In early June, COMPPARE Coordinators administered over 500 surveys to participants. The purpose of the surveys is to guide the design of the next…
What’s Next for COMPPARE?
Patient accrual has closed. Now, it’s up to participants to continue to complete COMPPARE’s Quality of Life and Side Effects Follow-up…
COMPPARE Completes Patient Enrollment
After four years and 2,524 enrolled patients, the COMPPARE team officially closed patient accrual to the study on October 31, 2022 at 11:59 p.m…
